Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
Lotfi, M
Morshedi Rad, D
Mashhadi, SS
Ashouri, A
Mojarrad, M
Mozaffari-Jovin, S
Farrokhi, S
Hashemi, M
Lotfi, M
Ebrahimi Warkiani, M
Abbaszadegan, MR
- Publisher:
- SPRINGER
- Publication Type:
- Journal Article
- Citation:
- Stem Cell Rev Rep, 2023, 19, (8), pp. 2576-2596
- Issue Date:
- 2023-11
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Lotfi, M | |
dc.contributor.author | Morshedi Rad, D | |
dc.contributor.author | Mashhadi, SS | |
dc.contributor.author | Ashouri, A | |
dc.contributor.author | Mojarrad, M | |
dc.contributor.author | Mozaffari-Jovin, S | |
dc.contributor.author | Farrokhi, S | |
dc.contributor.author | Hashemi, M | |
dc.contributor.author | Lotfi, M | |
dc.contributor.author |
Ebrahimi Warkiani, M https://orcid.org/0000-0002-4184-1944 |
|
dc.contributor.author | Abbaszadegan, MR | |
dc.date.accessioned | 2024-02-05T23:18:33Z | |
dc.date.available | 2023-06-30 | |
dc.date.available | 2024-02-05T23:18:33Z | |
dc.date.issued | 2023-11 | |
dc.identifier.citation | Stem Cell Rev Rep, 2023, 19, (8), pp. 2576-2596 | |
dc.identifier.issn | 2629-3269 | |
dc.identifier.issn | 2629-3277 | |
dc.identifier.uri | http://hdl.handle.net/10453/175325 | |
dc.description.abstract | Rapid advancement in genome editing technologies has provided new promises for treating neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a powerful gene editing tool offering advantages, including high editing efficiency and low cost over the conventional approaches. Human pluripotent stem cells (hPSCs), with their great proliferation and differentiation potential into different cell types, have been exploited in stem cell-based therapy. The potential of hPSCs and the capabilities of CRISPR/Cas9 genome editing has been paradigm-shifting in medical genetics for over two decades. Since hPSCs are categorized as hard-to-transfect cells, there is a critical demand to develop an appropriate and effective approach for CRISPR/Cas9 delivery into these cells. This review focuses on various strategies for CRISPR/Cas9 delivery in stem cells. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | SPRINGER | |
dc.relation | http://purl.org/au-research/grants/arc/DP200101860 | |
dc.relation.ispartof | Stem Cell Rev Rep | |
dc.relation.isbasedon | 10.1007/s12015-023-10585-3 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject.classification | 31 Biological sciences | |
dc.subject.mesh | Humans | |
dc.subject.mesh | CRISPR-Cas Systems | |
dc.subject.mesh | Gene Editing | |
dc.subject.mesh | Pluripotent Stem Cells | |
dc.subject.mesh | Cell Differentiation | |
dc.subject.mesh | Stem Cell Transplantation | |
dc.subject.mesh | Pluripotent Stem Cells | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Stem Cell Transplantation | |
dc.subject.mesh | Cell Differentiation | |
dc.subject.mesh | CRISPR-Cas Systems | |
dc.subject.mesh | Gene Editing | |
dc.subject.mesh | Humans | |
dc.subject.mesh | CRISPR-Cas Systems | |
dc.subject.mesh | Gene Editing | |
dc.subject.mesh | Pluripotent Stem Cells | |
dc.subject.mesh | Cell Differentiation | |
dc.subject.mesh | Stem Cell Transplantation | |
dc.title | Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells. | |
dc.type | Journal Article | |
utslib.citation.volume | 19 | |
utslib.location.activity | United States | |
pubs.organisational-group | University of Technology Sydney | |
pubs.organisational-group | University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2024-02-05T23:18:29Z | |
pubs.issue | 8 | |
pubs.publication-status | Published | |
pubs.volume | 19 | |
utslib.citation.issue | 8 |
Abstract:
Rapid advancement in genome editing technologies has provided new promises for treating neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a powerful gene editing tool offering advantages, including high editing efficiency and low cost over the conventional approaches. Human pluripotent stem cells (hPSCs), with their great proliferation and differentiation potential into different cell types, have been exploited in stem cell-based therapy. The potential of hPSCs and the capabilities of CRISPR/Cas9 genome editing has been paradigm-shifting in medical genetics for over two decades. Since hPSCs are categorized as hard-to-transfect cells, there is a critical demand to develop an appropriate and effective approach for CRISPR/Cas9 delivery into these cells. This review focuses on various strategies for CRISPR/Cas9 delivery in stem cells.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph